Literature DB >> 8470951

African swine fever virus specific porcine cytotoxic T cell activity.

C L Martins1, M J Lawman, T Scholl, C A Mebus, J K Lunney.   

Abstract

African swine fever virus (ASFV) specific, cytotoxic T lymphocyte (CTL) activity has been studied in a protection model in which SLA inbred miniature swine are experimentally inoculated with a naturally occurring, non-fatal ASFV isolate (NHV). Peripheral blood mononuclear cells (PBMC) from such infected swine show significant activity in CTL assays, using cultured ASFV-infected porcine blood derived macrophages as target cells. This CTL activity is elicited from PBMC by in vitro restimulation of effector cells with low doses (multiplicity of infection = 0.1) of the homologous virus isolate for 48 to 72 h. For SLAc/c effectors, this CTL activity appears to be SLA class I restricted because (1) blocking target cell antigens with monoclonal antibodies (mAb) against SLA class I antigens causes a major reduction in CTL activity; (2) there is preferential lysis of SLA class I matched, ASFV infected targets; and (3) depletion of effector cells with CD8 specific mAb and complement causes a reduction in CTL activity. The CTL activity is ASFV specific for all pigs tested in that infected macrophages are preferentially lysed as compared to normal (non-infected) cultured macrophages or macrophages infected with hog cholera virus (HCV). Lysis of macrophages infected with different ASFV isolates revealed that there is marked lysis of macrophages infected with the virulent L60 isolate but less lysis of macrophages infected with the DR-II and Tengani isolates. In summary, our data show that ASFV specific CTL activity is triggered in swine infected with the NHV ASFV isolate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8470951     DOI: 10.1007/bf01316896

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  31 in total

1.  HA2 subunit of influenza A H1 and H2 subtype viruses induces a protective cross-reactive cytotoxic T lymphocyte response.

Authors:  K Kuwano; M Scott; J F Young; F A Ennis
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

Review 2.  The host response to African swine fever virus.

Authors:  R C Wardley; S G Norley; C V Martins; M J Lawman
Journal:  Prog Med Virol       Date:  1987

3.  Recognition of influenza-infected cells by cytolytic T lymphocyte clones: determinant selection by class I restriction elements.

Authors:  A Vitiello; L A Sherman
Journal:  J Immunol       Date:  1983-10       Impact factor: 5.422

4.  Studies to determine the presence of neutralizing antibody in sera and kidneys from swine recovered from African swine fever.

Authors:  C J De Boer; W R Hess; A H Dardiri
Journal:  Arch Gesamte Virusforsch       Date:  1969

5.  The development and analysis of species specific and cross reactive monoclonal antibodies to leukocyte differentiation antigens and antigens of the major histocompatibility complex for use in the study of the immune system in cattle and other species.

Authors:  W C Davis; S Marusic; H A Lewin; G A Splitter; L E Perryman; T C McGuire; J R Gorham
Journal:  Vet Immunol Immunopathol       Date:  1987-07       Impact factor: 2.046

6.  Expression of T-cell associated antigens by porcine natural killer cells.

Authors:  M D Pescovitz; M A Lowman; D H Sachs
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

7.  Investigation of porcine natural-killer cell activity with reference to African swine-fever virus infection.

Authors:  S G Norley; R C Wardley
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

8.  Murine anti-swine T4 and T8 monoclonal antibodies: distribution and effects on proliferative and cytotoxic T cells.

Authors:  M D Pescovitz; J K Lunney; D H Sachs
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

9.  In vitro induction of swine peripheral blood monocyte proliferation by the fibroblast-derived murine hematopoietic growth factor CSF-1.

Authors:  E V Genovesi; R C Knudsen; D J Gerstner; D M Card; C L Martins; J C Quintero; T C Whyard
Journal:  Vet Immunol Immunopathol       Date:  1989-12       Impact factor: 2.046

10.  Swine leukocyte antigen and macrophage marker expression on both African swine fever virus-infected and non-infected primary porcine macrophage cultures.

Authors:  M Gonzalez Juarrero; C A Mebus; R Pan; Y Revilla; J M Alonso; J K Lunney
Journal:  Vet Immunol Immunopathol       Date:  1992-05       Impact factor: 2.046

View more
  17 in total

1.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  African Swine Fever Virus Georgia Isolate Harboring Deletions of MGF360 and MGF505 Genes Is Attenuated in Swine and Confers Protection against Challenge with Virulent Parental Virus.

Authors:  Vivian O'Donnell; Lauren G Holinka; Douglas P Gladue; Brenton Sanford; Peter W Krug; Xiqiang Lu; Jonathan Arzt; Bo Reese; Consuelo Carrillo; Guillermo R Risatti; Manuel V Borca
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

3.  Vaccine-induced, pseudorabies virus-specific, extrathymic CD4+CD8+ memory T-helper cells in swine.

Authors:  B T Ober; A Summerfield; C Mattlinger; K H Wiesmüller; G Jung; E Pfaff; A Saalmüller; H J Rziha
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

4.  The progressive adaptation of a georgian isolate of African swine fever virus to vero cells leads to a gradual attenuation of virulence in swine corresponding to major modifications of the viral genome.

Authors:  Peter W Krug; Lauren G Holinka; Vivian O'Donnell; Bo Reese; Brenton Sanford; Ignacio Fernandez-Sainz; Douglas P Gladue; Jonathan Arzt; Luis Rodriguez; Guillermo R Risatti; Manuel V Borca
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

5.  ELISpot Assay for the Detection of ASFV-Specific Interferon-Gamma (IFN-γ)-Producing Cells.

Authors:  Raquel Portugal
Journal:  Methods Mol Biol       Date:  2022

6.  Induction of Robust Immune Responses in Swine by Using a Cocktail of Adenovirus-Vectored African Swine Fever Virus Antigens.

Authors:  Shehnaz Lokhandwala; Suryakant D Waghela; Jocelyn Bray; Cameron L Martin; Neha Sangewar; Chloe Charendoff; Rashmi Shetti; Clay Ashley; Chang-Hsin Chen; Luc R Berghman; Duncan Mwangi; Paul J Dominowski; Dennis L Foss; Sharath Rai; Shaunak Vora; Lindsay Gabbert; Thomas G Burrage; David Brake; John Neilan; Waithaka Mwangi
Journal:  Clin Vaccine Immunol       Date:  2016-11-04

7.  Different routes and doses influence protection in pigs immunised with the naturally attenuated African swine fever virus isolate OURT88/3.

Authors:  Pedro J Sánchez-Cordón; Dave Chapman; Tamara Jabbar; Ana L Reis; Lynnette Goatley; Christopher L Netherton; Geraldine Taylor; Maria Montoya; Linda Dixon
Journal:  Antiviral Res       Date:  2016-11-28       Impact factor: 5.970

8.  The low-virulent African swine fever virus (ASFV/NH/P68) induces enhanced expression and production of relevant regulatory cytokines (IFNalpha, TNFalpha and IL12p40) on porcine macrophages in comparison to the highly virulent ASFV/L60.

Authors:  S Gil; N Sepúlveda; E Albina; A Leitão; C Martins
Journal:  Arch Virol       Date:  2008-09-12       Impact factor: 2.574

9.  DNA vaccination partially protects against African swine fever virus lethal challenge in the absence of antibodies.

Authors:  Jordi M Argilaguet; Eva Pérez-Martín; Miquel Nofrarías; Carmina Gallardo; Francesc Accensi; Anna Lacasta; Mercedes Mora; Maria Ballester; Ivan Galindo-Cardiel; Sergio López-Soria; José M Escribano; Pedro A Reche; Fernando Rodríguez
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

Review 10.  Approaches and Perspectives for Development of African Swine Fever Virus Vaccines.

Authors:  Marisa Arias; Ana de la Torre; Linda Dixon; Carmina Gallardo; Ferran Jori; Alberto Laddomada; Carlos Martins; R Michael Parkhouse; Yolanda Revilla; Fernando And Jose-Manuel Rodriguez
Journal:  Vaccines (Basel)       Date:  2017-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.